



## **LEADERSHIP AND BOARD OF DIRECTOR**

**Mark Pittenger, PhD**

**Chief Technology Officer Stem Cell Biology KOL**

Dr. Mark F. Pittenger is an integral member of the TargaCell team, a recognized expert in stem cells, and a long-time scientific advisor before TargaCell's founding. He has 30+ years of research experience and extensive training in biochemistry, cellular and molecular biology.

He is a Consultant for regenerative medicine and stem cell therapy for academia and industry. Currently, he is the CSO for startup Immunosity, Inc. He was a visiting scientist at Johns Hopkins Medical School and the University of Maryland School of Medicine. Formerly, Mark was the Chief Executive Officer of Pearl LifeScience Partners, LLC. Before Pearl, he worked for 10+ years for Osiris Therapeutics as a Senior Research Scientist, Manager of Cell Biology, Director of Discovery Research, and then the Vice President for Research, performing extensive studies on the isolation, characterization, and differentiation of the multi-potential stem cells from adult bone marrow known as mesenchymal stem cells (MSCs). He was a Member of the Scientific Advisory Board of Opexa Therapeutics, Inc.

Mark is a sought-after consultant and speaker for international meetings on stem cell biology and regenerative medicine. Mark's 1999 Science paper on clonally derived MSCs that established that MSCs were multipotent has been cited in over 27,000 publications. His work in MSC immunology (over 6000 citations) and MSC therapeutic development for cardiology (over 6000 citations) are also highly impactful. He is an inventor on 20 issued United States patents.

Dr. Pittenger received his Ph.D. from The Johns Hopkins Medical School and was a post-doctoral research fellow at Yale University and Cold Spring Harbor Laboratory.